Phase 2 Study of Stem Cell Educator Therapy in Type 1 Diabetes View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2010-2014

ABSTRACT

The translational potential to the clinical applications of cord blood stem cells has increased enormously in recent years, mainly because of its unique advantages including no risk to the donor, no ethical issues, low risk of graft-versus-host disease (GVHD), rapid availability, and large resource worldwide. Human cord blood contains several types of stem cells such as the umbilical cord blood-derived multipotent stem cells (CB-SC). CB-SC possess multiple biological properties including the expression of embryonic stem (ES) cell characteristics, giving rise to different types of cells and immune modulation. Specifically, CB-SC can function as an immune modulator that can lead to control of the immune responses, which could in turn be used as a new approach to overcome the autoimmunity of Type 1 diabetes (T1D) in patients1 and nonobese diabetic (NOD) mice. Here, the investigators develop a novel Stem Cell Educator therapy by using CB-SC and explore the therapeutic effectiveness of Educator therapy in T1D patients. More... »

URL

https://clinicaltrials.gov/show/NCT01350219

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "The translational potential to the clinical applications of cord blood stem cells has increased enormously in recent years, mainly because of its unique advantages including no risk to the donor, no ethical issues, low risk of graft-versus-host disease (GVHD), rapid availability, and large resource worldwide. Human cord blood contains several types of stem cells such as the umbilical cord blood-derived multipotent stem cells (CB-SC). CB-SC possess multiple biological properties including the expression of embryonic stem (ES) cell characteristics, giving rise to different types of cells and immune modulation. Specifically, CB-SC can function as an immune modulator that can lead to control of the immune responses, which could in turn be used as a new approach to overcome the autoimmunity of Type 1 diabetes (T1D) in patients1 and nonobese diabetic (NOD) mice. Here, the investigators develop a novel Stem Cell Educator therapy by using CB-SC and explore the therapeutic effectiveness of Educator therapy in T1D patients.", 
    "endDate": "2014-09-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT01350219", 
    "keywords": [
      "Phase 2", 
      "stem cell", 
      "type 1 diabetes", 
      "clinical application", 
      "cord blood stem cell", 
      "unique advantage", 
      "risk", 
      "Tissue Donor", 
      "ethic", 
      "low risk", 
      "Graft vs Host Disease", 
      "RAPID", 
      "large resource", 
      "human cord blood", 
      "multipotent stem cell", 
      "CB", 
      "biological property", 
      "expression", 
      "embryonic stem", 
      "characteristic", 
      "rise", 
      "different type", 
      "cell", 
      "immune modulation", 
      "immune modulators", 
      "control", 
      "immune response", 
      "autoimmunity", 
      "T1D", 
      "nonobese", 
      "NOD", 
      "mouse", 
      "therapy", 
      "therapeutic effectiveness", 
      "educator", 
      "T1D patient"
    ], 
    "name": "Phase 2 Study of Stem Cell Educator Therapy in Type 1 Diabetes", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT01350219"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00010.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.440258.f", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.411052.3", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.453053.4", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.452458.a", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.452708.c", 
        "type": "Organization"
      }
    ], 
    "startDate": "2010-09-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1016/j.ebiom.2015.11.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002033735"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11892-012-0308-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005456338", 
          "https://doi.org/10.1007/s11892-012-0308-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.autrev.2010.08.011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005647906"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0004226", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047015427"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1741-7015-10-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049280159", 
          "https://doi.org/10.1186/1741-7015-10-3"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT01350219"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT01350219'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT01350219'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT01350219'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT01350219'


 

This table displays all metadata directly associated to this object as RDF triples.

80 TRIPLES      16 PREDICATES      60 URIs      45 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT01350219 schema:about anzsrc-for:3103
2 schema:description The translational potential to the clinical applications of cord blood stem cells has increased enormously in recent years, mainly because of its unique advantages including no risk to the donor, no ethical issues, low risk of graft-versus-host disease (GVHD), rapid availability, and large resource worldwide. Human cord blood contains several types of stem cells such as the umbilical cord blood-derived multipotent stem cells (CB-SC). CB-SC possess multiple biological properties including the expression of embryonic stem (ES) cell characteristics, giving rise to different types of cells and immune modulation. Specifically, CB-SC can function as an immune modulator that can lead to control of the immune responses, which could in turn be used as a new approach to overcome the autoimmunity of Type 1 diabetes (T1D) in patients1 and nonobese diabetic (NOD) mice. Here, the investigators develop a novel Stem Cell Educator therapy by using CB-SC and explore the therapeutic effectiveness of Educator therapy in T1D patients.
3 schema:endDate 2014-09-01T00:00:00Z
4 schema:keywords CB
5 Graft vs Host Disease
6 NOD
7 Phase 2
8 RAPID
9 T1D
10 T1D patient
11 Tissue Donor
12 autoimmunity
13 biological property
14 cell
15 characteristic
16 clinical application
17 control
18 cord blood stem cell
19 different type
20 educator
21 embryonic stem
22 ethic
23 expression
24 human cord blood
25 immune modulation
26 immune modulators
27 immune response
28 large resource
29 low risk
30 mouse
31 multipotent stem cell
32 nonobese
33 rise
34 risk
35 stem cell
36 therapeutic effectiveness
37 therapy
38 type 1 diabetes
39 unique advantage
40 schema:name Phase 2 Study of Stem Cell Educator Therapy in Type 1 Diabetes
41 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT01350219
42 schema:sdDatePublished 2019-03-07T15:24
43 schema:sdLicense https://scigraph.springernature.com/explorer/license/
44 schema:sdPublisher N607393a885ec41f5a1dc8bbfa303ffac
45 schema:sponsor https://www.grid.ac/institutes/grid.411052.3
46 https://www.grid.ac/institutes/grid.440258.f
47 https://www.grid.ac/institutes/grid.452458.a
48 https://www.grid.ac/institutes/grid.452708.c
49 https://www.grid.ac/institutes/grid.453053.4
50 schema:startDate 2010-09-01T00:00:00Z
51 schema:subjectOf sg:pub.10.1007/s11892-012-0308-1
52 sg:pub.10.1186/1741-7015-10-3
53 https://doi.org/10.1016/j.autrev.2010.08.011
54 https://doi.org/10.1016/j.ebiom.2015.11.003
55 https://doi.org/10.1371/journal.pone.0004226
56 schema:url https://clinicaltrials.gov/show/NCT01350219
57 sgo:license sg:explorer/license/
58 sgo:sdDataset clinical_trials
59 rdf:type schema:MedicalStudy
60 N607393a885ec41f5a1dc8bbfa303ffac schema:name Springer Nature - SN SciGraph project
61 rdf:type schema:Organization
62 anzsrc-for:3103 schema:inDefinedTermSet anzsrc-for:
63 rdf:type schema:DefinedTerm
64 sg:pub.10.1007/s11892-012-0308-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005456338
65 https://doi.org/10.1007/s11892-012-0308-1
66 rdf:type schema:CreativeWork
67 sg:pub.10.1186/1741-7015-10-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049280159
68 https://doi.org/10.1186/1741-7015-10-3
69 rdf:type schema:CreativeWork
70 https://doi.org/10.1016/j.autrev.2010.08.011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005647906
71 rdf:type schema:CreativeWork
72 https://doi.org/10.1016/j.ebiom.2015.11.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002033735
73 rdf:type schema:CreativeWork
74 https://doi.org/10.1371/journal.pone.0004226 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047015427
75 rdf:type schema:CreativeWork
76 https://www.grid.ac/institutes/grid.411052.3 schema:Organization
77 https://www.grid.ac/institutes/grid.440258.f schema:Organization
78 https://www.grid.ac/institutes/grid.452458.a schema:Organization
79 https://www.grid.ac/institutes/grid.452708.c schema:Organization
80 https://www.grid.ac/institutes/grid.453053.4 schema:Organization
 




Preview window. Press ESC to close (or click here)


...